Literature DB >> 26130187

Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD).

Adam R Thode1, Robert A Latkany.   

Abstract

Meibomian gland (MG) dysfunction (MGD) is a multifactorial, chronic condition of the eyelids, leading to eye irritation, inflammation and ocular surface disease. Initial conservative therapy often includes a combination of warm compresses in addition to baby shampoo or eyelid wipes. The practice of lid hygiene dates back to the 1950s, when selenium sulfide-based shampoo was first used to treat seborrhoeic dermatitis of the eyelids. Today, tear-free baby shampoo has replaced dandruff shampoo for MGD treatment and offers symptom relief in selected patients. However, many will not achieve significant improvement on this therapy alone; some may even develop an allergy to the added dyes and fragrances in these products. Other manual and mechanical techniques to treat MGD include MG expression and massage, MG probing and LipiFlow(®). While potentially effective in patients with moderate MGD, these procedures are more invasive and may be cost prohibitive. Pharmacological treatments are another course of action. Supplements rich in omega-3 fatty acids have been shown to improve both MGD and dry eye symptoms. Tea tree oil, specifically the terpenin-4-ol component, is especially effective in treating MGD associated with Demodex mites. Topical antibiotics, such as azithromycin, or systemic antibiotics, such as doxycycline or azithromycin, can improve MGD symptoms both by altering the ocular flora and through anti-inflammatory mechanisms. Addressing and treating concurrent ocular allergy is integral to symptom management. Topical N-acetylcysteine and topical cyclosporine can both be effective therapeutic adjuncts in patients with concurrent dry eye. A short course of topical steroid may be used in some severe cases, with monitoring for steroid-induced glaucoma and cataracts. While the standard method to treat MGD is simply warm compresses and baby shampoo, a more tailored approach to address the multiple aetiologies of the disease is suggested.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130187     DOI: 10.1007/s40265-015-0432-8

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  48 in total

1.  Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction.

Authors:  Henry D Perry; Sima Doshi-Carnevale; Eric D Donnenfeld; Renée Solomon; Seth A Biser; Adam H Bloom
Journal:  Cornea       Date:  2006-02       Impact factor: 2.651

2.  Meibomian gland function and giant papillary conjunctivitis.

Authors:  W D Mathers; M Billborough
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

Review 3.  The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee.

Authors:  J Daniel Nelson; Jun Shimazaki; Jose M Benitez-del-Castillo; Jennifer P Craig; James P McCulley; Seika Den; Gary N Foulks
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

4.  Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction.

Authors:  Steven L Maskin
Journal:  Cornea       Date:  2010-10       Impact factor: 2.651

5.  Complete androgen insensitivity syndrome: effect on human meibomian gland secretions.

Authors:  Benjamin D Sullivan; James E Evans; Jennifer M Cermak; Kathleen L Krenzer; M Reza Dana; David A Sullivan
Journal:  Arch Ophthalmol       Date:  2002-12

6.  Chronic eyelid dermatitis secondary to cocamidopropyl betaine allergy in a patient using baby shampoo eyelid scrubs.

Authors:  John D Welling; Thomas F Mauger; Lynn R Schoenfield; Andrew J Hendershot
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

7.  Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment.

Authors:  Jack V Greiner
Journal:  Clin Exp Ophthalmol       Date:  2012-12-14       Impact factor: 4.207

8.  Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.

Authors:  Gail L Torkildsen; Paul Cockrum; Edward Meier; William M Hammonds; Bruce Silverstein; Steven Silverstein
Journal:  Curr Med Res Opin       Date:  2010-12-07       Impact factor: 2.580

9.  A new system, the LipiFlow, for the treatment of meibomian gland dysfunction.

Authors:  Stephen S Lane; Harvey B DuBiner; Randy J Epstein; Paul H Ernest; Jack V Greiner; David R Hardten; Edward J Holland; Michael A Lemp; James E McDonald; David I Silbert; Caroline A Blackie; Christy A Stevens; Raman Bedi
Journal:  Cornea       Date:  2012-04       Impact factor: 2.651

10.  Classification of chronic blepharitis.

Authors:  J P McCulley; J M Dougherty; D G Deneau
Journal:  Ophthalmology       Date:  1982-10       Impact factor: 12.079

View more
  31 in total

Review 1.  Advances in dry eye disease treatment.

Authors:  Erin C O'Neil; Matthew Henderson; Mina Massaro-Giordano; Vatinee Y Bunya
Journal:  Curr Opin Ophthalmol       Date:  2019-05       Impact factor: 3.761

2.  Compliance and Subjective Patient Responses to Eyelid Hygiene.

Authors:  Yousef A Alghamdi; Andrew Camp; William Feuer; Carol L Karp; Sarah Wellik; Anat Galor
Journal:  Eye Contact Lens       Date:  2017-07       Impact factor: 2.018

Review 3.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 4.  Intense Pulsed Light Therapy In The Treatment Of Meibomian Gland Dysfunction: Current Perspectives.

Authors:  Giuseppe Giannaccare; Leonardo Taroni; Carlotta Senni; Vincenzo Scorcia
Journal:  Clin Optom (Auckl)       Date:  2019-10-17

5.  Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction.

Authors:  Ho-Yun Kim; Ji-Eun Lee; Ha-Na Oh; Ju-Whan Song; Sang-Youp Han; Jong-Soo Lee
Journal:  Int J Ophthalmol       Date:  2018-04-18       Impact factor: 1.779

6.  Effect of topical loteprednol etabonate with lid hygiene on tear cytokines and meibomian gland dysfunction in prosthetic eye wearers.

Authors:  J S Ko; Y Seo; M K Chae; S Y Jang; J S Yoon
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 7.  Neuropathic Corneal Pain: Approaches for Management.

Authors:  Gabriela Dieckmann; Sunali Goyal; Pedram Hamrah
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

8.  Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction.

Authors:  Steven L Maskin; Whitney R Testa
Journal:  Br J Ophthalmol       Date:  2017-06-07       Impact factor: 4.638

Review 9.  Intense pulsed light for evaporative dry eye disease.

Authors:  Steven J Dell
Journal:  Clin Ophthalmol       Date:  2017-06-20

10.  Evaluation of Monocular Treatment for Meibomian Gland Dysfunction with an Automated Thermodynamic System in Elderly Chinese Patients: A Contralateral Eye Study.

Authors:  Yinying Zhao; Jialu Xie; Junhua Li; Yana Fu; Xiaolei Lin; Shangrong Wang; Jiling Ma; Yune Zhao
Journal:  J Ophthalmol       Date:  2016-12-27       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.